REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that company Chief Executive Officer Ken Kelley will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the Investor Forum features presentations from leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
“PaxVax is at an important inflection point catalyzed by our acquisition of Vivotif, a globally marketed vaccine for typhoid, and the anticipated BLA approval and launch next year of our second commercial product, a single-dose oral cholera vaccine candidate,” said Mr. Kelley. “I am looking forward to discussing our progress in more detail at the BIO Investor Forum.”
PaxVax has focused on the acquisition and development of effective, safe, affordable and easy-to-administer vaccines for travelers. The company is currently manufacturing the FDA-approved typhoid vaccine Vivotif® and marketing it in 27 countries, including the U.S. PaxVax’s pipeline includes a vaccine candidate for cholera, PXVX0200, which is nearing completion of its Phase 3 clinical trials and was granted FDA Fast Track designation as there is no vaccine available in the U.S. against this infectious disease. PaxVax also intends to develop a hepatitis A vaccine for travelers and has a pipeline of early-stage travel vaccine candidates for dengue, malaria and rabies.
Mr. Kelley will present on Tuesday, October 7, 2014 at 11:00 am Pacific Time in the Pacific Heights room. For more information on the BIO Investor Forum, please visit: http://www.bio.org/events/conferences/13th-annual-bio-investor-forum.
Founded in 2007, PaxVax is a fully integrated specialty vaccine company with a mission to protect people from infectious diseases. The company seeks both financial returns through two specialty business strategies in travel and biodefense vaccines as well as social returns by providing access to its vaccines globally and by developing vaccines addressing some of the world’s most lethal infectious diseases. The PaxVax portfolio includes a licensed vaccine for typhoid (Vivotif), vaccines in clinical development for cholera, anthrax, HIV, and H5N1 (pandemic bird flu) and in research for malaria, dengue, rabies and HSV. The company also intends to develop a hepatitis A vaccine for travelers. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and its newly acquired facility near Bern, Switzerland. More information is available at www.PaxVax.com.